{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:22:45Z","timestamp":1782285765288,"version":"3.54.5"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[1998,9,1]],"date-time":"1998-09-01T00:00:00Z","timestamp":904608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although the antiresorptive agent alendronate has been shown to increase bone mineral density (BMD) at the hip and spine and decrease the incidence of osteoporotic fractures in older women, few data are available regarding early prediction of long-term response to therapy, particularly with regard to increases in hip BMD. Examining short-term changes in biochemical markers incorporates physiologic response with therapeutic compliance and should provide useful prognostic information for patients. The objective of this study was to examine whether early changes in biochemical markers of bone turnover predict long-term changes in hip BMD in elderly women. The study was a double-blind, placebo-controlled, randomized clinical trial which took place in a community-based academic hospital. One hundred and twenty community-dwelling, ambulatory women 65 years of age and older participated in the study. Intervention consisted of alendronate versus placebo for 2.5 years. All patients received appropriate calcium and vitamin D supplementation. The principal outcome measures included BMD of the hip (total hip, femoral neck, trochanter, and intertrochanter), spine (posteroanterior [PA] and lateral), total body, and radius. Biochemical markers of bone resorption included urinary N-telopeptide cross-linked collagen type I and free deoxypyridinoline; markers of bone formation included serum osteocalcin and bone-specific alkaline phosphatase. Long-term alendronate therapy was associated with increased BMD at the total hip (4.0%), femoral neck (3.1%), trochanter (5.5%), intertrochanter (3.8%), PA spine (7.8%), lateral spine (10.6%), total body (2.2%), and one-third distal radius (1.3%) in elderly women (all p &amp;lt; 0.01). In the placebo group, bone density increased 1.9\u20132.1% at the spine (p &amp;lt; 0.05) and remained stable at all other sites. At 6 months, there were significant decreases in all markers of bone turnover (\u201310% to \u201353%, p &amp;lt; 0.01) in women on alendronate. The changes in urinary cross-linked collagen at 6 months correlated with long-term bone density changes at the hip (r = \u20130.35, p &amp;lt; 0.01), trochanter (r = \u20130.36, p &amp;lt; 0.01), PA spine (r = \u20130.41, p &amp;lt; 0.01), and total body (r = \u20130.34, p &amp;lt; 0.05). At 6 months, patients with the greatest drop in urinary cross-linked collagen (65% or more) demonstrated the greatest gains in total hip, trochanteric, and vertebral bone density (all p &amp;lt; 0.05). A 30% decrease in urinary cross-linked collagen at 6 months predicted a bone density increase of 2.8\u20134.1% for the hip regions and 5.8\u20136.9% for the spine views at the 2.5-year time point (p &amp;lt; 0.05). There were no substantive associations between changes in biochemical markers and bone density in the placebo group. Alendronate therapy was associated with significant long-term gains in BMD at all clinically relevant sites, including the hip, in elderly women. Moreover, these improvements were associated with early decreases in biochemical markers of bone turnover. Early dynamic decreases in urinary cross-linked collagen can be used to monitor and predict long-term response to bisphosphonate therapy in elderly women. Future studies are needed to determine if early assessment improves long-term patient compliance or uncovers poor compliance, thereby aiding the physician in maximizing the benefits of therapy.<\/jats:p>","DOI":"10.1359\/jbmr.1998.13.9.1431","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:05:00Z","timestamp":1146096300000},"page":"1431-1438","source":"Crossref","is-referenced-by-count":185,"title":["Early Changes in Biochemical Markers of Bone Turnover Predict the Long-Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical Trial"],"prefix":"10.1093","volume":"13","author":[{"given":"Susan L.","family":"Greenspan","sequence":"first","affiliation":[{"name":"Charles A. Dana Research Institute, General Clinical Research Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, U.S.A."},{"name":"Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, U.S.A."},{"name":"Division of Bone and Mineral Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Parker","sequence":"additional","affiliation":[{"name":"Biometrics Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, U.S.A."},{"name":"Charles A. Dana Research Institute, General Clinical Research Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Division of Bone and Mineral Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold N.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, U.S.A."},{"name":"Division of Bone and Mineral Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri","family":"Maitland-Ramsey","sequence":"additional","affiliation":[{"name":"Division of Bone and Mineral Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Karpf","sequence":"additional","affiliation":[{"name":"Roche Global Development, Palo Alto, California, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020713275854000_bib1","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jbmr.5650070902","article-title":"How many women have osteoporosis?","volume":"7","author":"Melton","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024020713275854000_bib2","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1001\/archinte.1991.00400100100017","article-title":"A model of lifetime osteoporosis impact","volume":"151","author":"Chrischilles","year":"1991","journal-title":"Arch Intern Med"},{"key":"2024020713275854000_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-117-1-1","article-title":"Treatment of postmenopausal osteoporosis with transdermal estrogen","volume":"117","author":"Lufkin","year":"1992","journal-title":"Ann Intern Med"},{"key":"2024020713275854000_bib4","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"Effects of hormone therapy on bone mineral density","volume":"276","author":"The Writing Group for the PEPI Trial","year":"1996","journal-title":"JAMA"},{"key":"2024020713275854000_bib5","first-page":"290","article-title":"Estrogen treatment of patients with osteoporosis","volume":"76","author":"Lindsay","year":"1990","journal-title":"Obstet Gynecol"},{"key":"2024020713275854000_bib6","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2024020713275854000_bib7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/bmj.305.6853.556","article-title":"Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study","volume":"305","author":"Overgaard","year":"1992","journal-title":"BMJ"},{"key":"2024020713275854000_bib8","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of treatment with oral alendronate on bone mineral density and fracture incidence in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2024020713275854000_bib9","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jama.1997.03540380073035","article-title":"for the Alendronate Osteoporosis Treatment Study Groups Prevention of nonvertebral fractures by alendronate: A meta-analysis","volume":"277","author":"Karpf","year":"1997","journal-title":"JAMA"},{"key":"2024020713275854000_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s002239900135","article-title":"Biochemical markers of bone turnover reflect femoral bone loss in elderly women","volume":"59","author":"Dresner-Pollak","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"2024020713275854000_bib11","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020713275854000_bib12","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713275854000_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0140-6736(93)92555-8","article-title":"Bone density at various sites for prediction of hip fractures","volume":"341","author":"Cummings","year":"1993","journal-title":"Lancet"},{"issue":"Suppl 3","key":"2024020713275854000_bib14","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/BF01623002","article-title":"Clinical pharmacology of alendronate sodium","volume":"3","author":"Gertz","year":"1993","journal-title":"Osteoporos Int"},{"key":"2024020713275854000_bib15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ajcn\/46.4.685","article-title":"Dietary calcium intake and bone loss from the spine in healthy postmenopausal women","volume":"46","author":"Dawson-Hughes","year":"1987","journal-title":"Am J Clin Nutr"},{"key":"2024020713275854000_bib16","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/jbmr.5650091216","article-title":"Femoral bone loss progresses with age: A longitudinal study in women over age 65","volume":"9","author":"Greenspan","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024020713275854000_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF02509439","article-title":"Classification of osteoporosis in the elderly is dependent on site-specific analysis","volume":"58","author":"Greenspan","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"2024020713275854000_bib18","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/jbmr.5650071119","article-title":"A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine","volume":"7","author":"Hanson","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024020713275854000_bib19","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/jbmr.5650091019","article-title":"Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption","volume":"9","author":"Robins","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024020713275854000_bib20","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/clinchem\/41.11.1560","article-title":"Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum","volume":"41","author":"Gomez","year":"1995","journal-title":"Clin Chem"},{"key":"2024020713275854000_bib21","first-page":"265","article-title":"for the Alendronate Elderly Osteoporosis Study Centers dose-response relationships for alendronate treatment in osteoporotic elderly women","volume":"82","author":"Bone","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713275854000_bib22","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/jbmr.5650091121","article-title":"Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis","volume":"9","author":"Rossini","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024020713275854000_bib23","first-page":"1399","article-title":"The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women","volume":"76","author":"Harris","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl","key":"2024020713275854000_bib24","first-page":"S150","article-title":"Biochemical markers predict spine but not hip BMD response to alendronate: The fracture intervention trial (FIT)","volume":"12","author":"Bauer","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024020713275854000_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jama.1994.03510260060029","article-title":"Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly","volume":"271","author":"Greenspan","year":"1994","journal-title":"JAMA"},{"key":"2024020713275854000_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.7326\/0003-4819-111-5-355","article-title":"Baseline measurement of bone mass predicts fractures in white women","volume":"111","author":"Hui","year":"1989","journal-title":"Ann Intern Med"},{"key":"2024020713275854000_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/BF00316285","article-title":"Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover","volume":"54","author":"Rosen","year":"1994","journal-title":"Calcif Tissue Int"},{"key":"2024020713275854000_bib28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jbmr.5650100418","article-title":"Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion","volume":"10","author":"Garnero","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024020713275854000_bib29","first-page":"1046","article-title":"Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease","volume":"77","author":"Garnero","year":"1993","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.1998.13.9.1431","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/13\/9\/1431\/56598477\/5650130910.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/13\/9\/1431\/56598477\/5650130910.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:57:05Z","timestamp":1710341825000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/13\/9\/1431-1438\/7514493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,9,1]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[1998,9,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.1998.13.9.1431","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1998,9,1]]},"published":{"date-parts":[[1998,9,1]]}}}